Qiagen buys SABiosciences
This article was originally published in The Gray Sheet
Executive Summary
Qiagen purchased the privately-held company for $90 million, adding preformatted, real-time polymerase chain reaction assay technology that can be used for the development of new diagnostics and for drug discovery and validation, the firm announced Nov. 9. SABiosciences is expected to add $24 million to Qiagen's 2010 revenues. The firm's technology targets the interaction of genes involved in diseases such as cancer and diabetes, as well as immune and cardiovascular disorders. The purchase of the Frederick, Md., firm is "highly synergistic" with Qiagen's September acquisition of personalized medicine diagnostics company DxS, Qiagen notes (1"The Gray Sheet" Sept. 28, 2009)
You may also be interested in...
Qiagen Buys DxS, Boasts "Deepest" Personalized Medicine Testing Pipeline
Qiagen is boasting the "deepest" pipeline of molecular diagnostics for personalized medicine after acquiring test maker DxS for $95 million, plus up to $35 million in milestone payments
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.